395 related articles for article (PubMed ID: 23815981)
1. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion.
Buhmann R; Simoes B; Stanglmaier M; Yang T; Faltin M; Bund D; Lindhofer H; Kolb HJ
Bone Marrow Transplant; 2009 Mar; 43(5):383-97. PubMed ID: 18850012
[TBL] [Abstract][Full Text] [Related]
3. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
[TBL] [Abstract][Full Text] [Related]
4. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
Schuster FR; Stanglmaier M; Woessmann W; Winkler B; Siepermann M; Meisel R; Schlegel PG; Hess J; Lindhofer H; Borkhardt A; Buhmann R
Br J Haematol; 2015 Apr; 169(1):90-102. PubMed ID: 25495919
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.
Porter DL; Levine BL; Bunin N; Stadtmauer EA; Luger SM; Goldstein S; Loren A; Phillips J; Nasta S; Perl A; Schuster S; Tsai D; Sohal A; Veloso E; Emerson S; June CH
Blood; 2006 Feb; 107(4):1325-31. PubMed ID: 16269610
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
9. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
[TBL] [Abstract][Full Text] [Related]
11. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
Slavin S; Nagler A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
14. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
16. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
19. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
20. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
